Author:
Mao Xin,Dai Zhanjing,Yang Jing,Wu Yuhang,Xie Fan,Lu Yun,Yu Jie,Chang Feng,Lu Yuqiong
Funder
Jiangsu Funding Program for Excellent Postdoctoral Talent
Ocumension Therapeutics Co., Ltd., Shanghai, China
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Zhang Y, Shao Y, Zhou Q. Progress in systemic treatments of non-infectious uveitis. Int Eye Sci. 2019;19(12):2045–7 ((in Chinese)).
2. Hu S, Xie C, Yang P, Huang X. An epidemiological survey of uveitis in southern China. Int Eye Sci. 2002;01:1–3.
3. Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500. https://doi.org/10.1016/j.ophtha.2003.06.014.
4. European Medicines Agency. EU/3/10/763—orphan designation for treatment of non-infectious uveitis affecting the posterior segment of the eye. 2010. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-10-763. Accessed 22 Oct 2023.
5. Chen Z. What's new about new drugs and devices. Hainan Dly. B06 (2022-07-28) (in Chinese).